Boston Scientific Acquires Silk Road Medical for $1.26 Billion

Silk Road Medical, a pioneer in the development of minimally invasive medical devices for carotid artery procedures, has announced that it has engaged in a definitive agreement to be acquired by Boston Scientific Corporation for $27.50 per share in cash. Silk Road is valued at approximately $1.26 billion under this transaction, which represents a nearly 38% increase over the volume-weighted average share price of the past 60 days. Upon its completion, Silk Road Medical will be a wholly-owned subsidiary of Boston Scientific, a global leader in medical technology. Boston Scientific's portfolio in the management of carotid artery disease and stroke prevention is anticipated to be improved by the acquisition.

Silk Road Medical, which is situated in Plymouth, Minnesota and Sunnyvale, California, is dedicated to the development of innovative medical devices that mitigate the risk of stroke. Its technology has had a substantial impact on the management of carotid artery disease, providing minimally invasive solutions to enhance patient outcomes. BofA Securities is serving as the exclusive financial advisor to Silk Road Medical, while Wilson Sonsini Goodrich & Rosati is acting as the legal advisor. Boston Scientific, a prominent medical technology company, continues to expand its capabilities and market reach through strategic acquisitions. This latest move aligns with its mission to advance patient care through innovative medical solutions.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

Read more